Cover Image
市場調查報告書

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98) :開發中產品分析

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364840
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98) :開發中產品分析 Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 81 Pages
簡介

本報告提供以組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98)概要

治療藥的開發

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):開發中的產品 - 各開發階段

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):開發中的產品 - 各治療範圍

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):開發中的產品 - 各適應症

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):企業開發中的產品

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):大學/機關開發中的產品

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98)治療藥的開發企業

  • 4SC AG
  • Chipscreen Biosciences Ltd
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • IRBM Science Park SpA
  • Merck & Co., Inc.
  • Sigma-Tau S.p.A.
  • Syndax Pharmaceuticals, Inc.
  • TetraLogic Pharmaceuticals

藥物簡介

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):暫停中的計劃

組蛋白去乙醯酵素3 (SMAP45或EC 3.5.1.98):主要消息與新聞稿

附錄

目錄
Product Code: GMDHC0108TDB

Summary

Global Markets Direct's, 'Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Review, H1 2016', provides in depth analysis on Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Overview
  • Therapeutics Development
    • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Products under Development by Stage of Development
    • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Products under Development by Therapy Area
    • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Products under Development by Indication
  • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Products under Development by Companies
  • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Products under Development by Universities/Institutes
  • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
    • 4SC AG
    • Chipscreen Biosciences Ltd
    • Curis, Inc.
    • GlaxoSmithKline Plc
    • HitGen LTD
    • IRBM Science Park SpA
    • Merck & Co., Inc.
    • Sigma-Tau S.p.A.
    • Syndax Pharmaceuticals, Inc.
    • TetraLogic Pharmaceuticals
  • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Drug Profiles
    • 4SC-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chidamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CUDC-907 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit HDAC-3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HG-3001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Largazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • N-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-3595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vorinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Dormant Projects
  • Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Featured News & Press Releases
    • Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
    • Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting
    • May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting
    • Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting
    • Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting
    • Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology
    • Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer
    • Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team
    • Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
    • Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting
    • Dec 03, 2015: Syndax Announces Multiple Data Presentations on Entinostat at Upcoming San Antonio Breast Cancer Symposium
    • Dec 01, 2015: Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin
    • Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting
    • Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
    • Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by 4SC AG, H1 2016
  • Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Pipeline by Curis, Inc., H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by HitGen LTD, H1 2016
  • Pipeline by IRBM Science Park SpA, H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by Sigma-Tau S.p.A., H1 2016
  • Pipeline by Syndax Pharmaceuticals, Inc., H1 2016
  • Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top